Tone change29 Feb 2024 06:22
We’ve gone from on the verge of a paradigm shift and. . ‘ we know what we’ve got’ to……
The Directors believe that, subject to the successful completion of clinical trials and receipt of the necessary regulatory approvals, AVA6000 has the potential to compete effectively against other approaches that limit the incidence and severity of doxorubicin related toxicities.